Vaxart, Inc. (VXRT) - Earnings growth in current year

Official company branding of Vaxart (VXRT)

Vaxart, Inc. (VXRT) is protected by exclusive patents for tablet vaccines, although strict FDA oversight limits its expansion. A lack of recurring revenue leaves the company dependent on investments and trials. This annual EPS growth chart visualizes the impact of these factors, where the 12.40 indicator determines the metric's magnitude. Logistic resilience is ensured through the diversification of delivery channels for essential components.

VXRT Vaxart Inc. Net earnings per share growth this year (07/04/2022 - 07/19/2025)

Comprehensive metric breakdowns and analytics for Vaxart, Inc. (VXRT)

- stock price and consensus target price:
Fundamental valuation:Vaxart, Inc.
Manufactured product of Vaxart Corp

This indicator reflects the year-over-year growth rate of net earnings per share, neutralizing the short-term volatility of quarterly reports. The calculation is based on comparing current results with the same period last year to identify a sustainable profitability trend. By analyzing annual EPS fluctuations, investors assess the monetization of the VAAST platform and the effectiveness of the oral vaccine patent portfolio of Vaxart, Inc. (VXRT).